Prairie Wealth Advisors Inc. lifted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 3.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,616 shares of the exchange traded fund’s stock after purchasing an additional 231 shares during the period. Prairie Wealth Advisors Inc.’s holdings in SPDR S&P Biotech ETF were worth $613,000 as of its most recent filing with the SEC.
Other large investors have also made changes to their positions in the company. ICA Group Wealth Management LLC acquired a new stake in SPDR S&P Biotech ETF in the 4th quarter valued at approximately $27,000. Scarborough Advisors LLC bought a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter valued at approximately $32,000. BOCHK Asset Management Ltd acquired a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter worth $36,000. ORG Partners LLC acquired a new stake in shares of SPDR S&P Biotech ETF in the second quarter worth $40,000. Finally, Vima LLC bought a new position in SPDR S&P Biotech ETF during the fourth quarter worth $45,000.
SPDR S&P Biotech ETF Price Performance
NYSEARCA:XBI opened at $98.75 on Wednesday. SPDR S&P Biotech ETF has a one year low of $63.80 and a one year high of $103.52. The company has a fifty day moving average price of $98.95 and a 200 day moving average price of $93.90. The stock has a market cap of $7.53 billion, a P/E ratio of 11.47 and a beta of 1.11.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- 3 Healthcare Dividend Stocks to Buy
- Why Small-Cap Stocks Could Be Ready to Outperform After Rate Cuts
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- FedEx Stock Dips: Why Analysts See a Quick Rebound Coming
- 3 REITs to Buy and Hold for the Long Term
- PayPal Soars to New Heights: Why Analysts See More Upside
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.